Key result
PNPLA2 gene therapy resolves myocardial lipid deposition in preclinical arrhythmogenic cardiomyopathy.
Why the study?
Arrhythmogenic cardiomyopathy is a severe heart disease with limited effective therapies and few mouse models fully replicate human myocardial lipid deposition.
Does PNPLA2 gene therapy resolve myocardial lipid deposition in arrhythmogenic cardiomyopathy?
Does PNPLA2 gene therapy resolve myocardial lipid deposition in arrhythmogenic cardiomyopathy?
PNPLA2 gene therapy may offer a novel approach to resolving myocardial lipid deposition in arrhythmogenic cardiomyopathy.
May support PNPLA2 gene therapy for arrhythmogenic cardiomyopathy; hypothesis-generating and requires clinical validation.
Arrhythmogenic cardiomyopathy (ACM) is a severe heart disease that is characterized by ventricular arrhythmia, systolic dysfunction, and the unique fibrofatty replacement of myocardium. ACM often leads to heart failure and sudden cardiac death, lacking effective and specific therapeutics except for heart transplantation.1 More than half of ACM cases are attributed to gene mutations, including the canonical desmosome-related genes such as PKP2, DSP, JUP, and DSG2, and other non-desmosome genes. However, few mouse models fully phenocopy human ACM phenotypes, particularly lipid deposition in the myocardium (Table 1).
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied Arrhythmogenic cardiomyopathy. PNPLA2 gene therapy was evaluated on Myocardial lipid deposition. PNPLA2 gene therapy resolves myocardial lipid deposition in arrhythmogenic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: